XLRN - Earnings announcements

Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 Data Outlines Alternatives by Which Acceleron Could Maximize Shareholder Value as Independent Company, Including by Monetizing Royalties Ready and Willing to Assist with Change in Board Composition to Better Position Company for Go-Forward Strategy Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately

Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong Commercial Performance, Including Opdivo's Return to Growth and Momentum across New Product Portfolio Achieves Significant Regulatory and Clinical Milestones across Product Pipeline Further Strengthens Pipeline through Disciplined Business Development Agreements, including with Agenus and Eisai Adjusts GAAP and Reaffirms Non-GAAP EPS Guidance for 2021 Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, co